News Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Delayed OTC Markets Other stock markets 01:00:56 2024-05-17 pm EDT			5-day change	1st Jan Change
0.006 ^USD	-25.93%		-25.93%	-80.00%

Jan. 18	Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	CI
Jan. 16	Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	Jan. 18	CI
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	Jan. 16	CI
Adhera Therapeutics, Inc. Announces Board Resignations	Jan. 16	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)	23-10-17	AQ
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?	23-08-10	PR
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding	23-06-21	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	23-04-27	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding	23-03-01	CI
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	23-02-15	CI
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	23-01-25	CI
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	22-12-14	CI
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Reverse Split: 1 of 20	22-10-05	FA
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist	22-09-19	AQ
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board	22-09-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Adhera Therapeutics, Inc.

Equities

ATRX

US00687E4061

Summary

Filters